Naringenin nano-delivery systems and their therapeutic applications

Bhia, Mohammed and Motallebi, Mahzad and Abadi, Banafshe and Zarepour, Atefeh and Pereira-Silva, Miguel and Saremnejad, Farinaz and Santos, Ana Cláudia and Zarrabi, Ali and Melero, Ana and Jafari, Seid Mahdi and Shakibaei, Mehdi (2021) Naringenin nano-delivery systems and their therapeutic applications. Pharmaceutics, 13 (2). ISSN 1999-4923

Full text not available from this repository. (Request a copy)


Naringenin (NRG) is a polyphenolic phytochemical belonging to the class of flavanones and is widely distributed in citrus fruits and some other fruits such as bergamot, tomatoes, cocoa, and cherries. NRG presents several interesting pharmacological properties, such as anti-cancer, antioxidant, and anti-inflammatory activities. However, the therapeutic potential of NRG is hampered due to its hydrophobic nature, which leads to poor bioavailability. Here, we review a wide range of nanocarriers that have been used as delivery systems for NRG, including polymeric nanoparticles, micelles, liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), nanosuspensions, and nanoemulsions. These nanomedicine formulations of NRG have been applied as a potential treatment for several diseases, using a wide range of in vitro, ex vivo, and in vivo models and different routes of administration. From this review, it can be concluded that NRG is a potential therapeutic option for the treatment of various diseases such as cancer, neurological disorders, liver diseases, ocular disorders, inflammatory diseases, skin diseases, and diabetes when formulated in the appropriate nanocarriers.
Item Type: Article
Uncontrolled Keywords: Antioxidants; Bioavailability; Drug delivery; Flavonoid; Nanomedicine; Nanoparticles; Naringenin; Natural products; Nutraceuticals
Divisions: Faculty of Engineering and Natural Sciences
Sabancı University Nanotechnology Research and Application Center
Depositing User: Ali Zarrabi
Date Deposited: 31 Aug 2022 13:54
Last Modified: 31 Aug 2022 13:54

Actions (login required)

View Item
View Item